Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06510855Not ApplicableActive Not Recruiting

DurAVR™ THV EU-EFS

Role: lead

NCT07194265Not ApplicableRecruiting

A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

Role: lead

NCT05712161Not ApplicableActive Not Recruiting

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study

Role: lead

NCT05182307Not ApplicableUnknown

DurAVR™ THV System: First-In-Human Study

Role: lead

NCT04178213Not ApplicableUnknown

First in Human Feasibility Study With ADAPT 3D - ALR for Aortic Leaflet Repair

Role: lead

NCT02629328Not ApplicableCompleted

CardioCel Tri-leaflet Repair Study

Role: lead

NCT02681341Completed

Vascular Post Market Review

Role: collaborator

All 7 trials loaded